Premium
AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT‐NAÏVE CLL/SLL
Author(s) -
Ghia P.,
Tam C.S.,
Siddiqi T.,
Stevens D.,
Flinn I.W.,
Russell K.,
Eckert K.,
Zhou C.,
Ninomoto J.,
James D.F.,
Wierda W.G.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2440_13
Subject(s) - medicine , ibrutinib , ighv@ , venetoclax , chemoimmunotherapy , fludarabine , oncology , rituximab , chlorambucil , regimen , cyclophosphamide , chemotherapy , chronic lymphocytic leukemia , leukemia , lymphoma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom